Yuhan USA to participate at 2024 BIO International Convention in June
Yuhan USA, a subsidiary of Yuhan Corporation, will be participating in 2024 BIO International Convention on June 3-6 (San Diego, CA).
Yuhan USA is looking for potential therapeutic assets with validated proof-of-concept data for in-licensing. The company’s R&D focus areas are Oncology (targeted therapy, immunotherapy for solid tumor), Obesity/Metabolism (incretin/non-incretins target), Fibrosis (lung, kidney) and Platform technology (TPD, Tumor/immune cell targeting delivery system, AI/Big data drug discovery).
About Yuhan USA
Yuhan USA is a global business development arm of Yuhan Corporation, based in Boston, MA. The company is actively seeking for business development and strategic partnership opportunities with global academic research centers, biotech startups, and pharmaceutical companies. The goal is to identify potential therapeutic assets with validated proof-of-concept data for potential in-licensing and strategic collaboration.
About Yuhan Corporation
Yuhan Corporation is one of the leading pharmaceutical companies in South Korea since 1926. The company has fully integrated R&D teams covering from discoveries to clinical developments, with a strong point in translational research. Yuhan Corporation researches, develops, manufactures, and sells pharmaceuticals and operates in six divisions: Pharmaceutical Business, Overseas Business (CDMO services), Research & Development, Household & Healthcare Business, Animal healthcare & Dental Business, and cGMP manufacturing.